Value creation
We focus on creating lasting value for society and our business with a strong commitment to our triple bottom line. Following the Novo Nordisk Way, we are dedicated to delivering long-term value for people with serious chronic diseases, our employees, partners, shareholders and society. Our value chain covers every stage from identifying new treatments through R&D, manufacturing, supplier partnerships and distribution to the people we serve.
Insights from patients, healthcare experts, partners and our employeesManufacturing capacity and raw materialsFinancial resources
Paid out close to DKK 52 billion
via dividends to shareholders, including Novo Holdings A/S
– mainly in production capacity – to meet demand for current and future products Reached more than 45.6 million people living with obesity and diabetes Reached 7.1 million vulnerable people living with diabetes
The Novo Nordisk Foundation holds
77.3% of votes and 28.1% of shares in Novo Nordisk A/S through Novo Holdings A/S.
Our ownership and governance model supports sustainable growth by aligning long-term value creation with short-term performance transparency.
The Novo Nordisk Foundation has three strategic focus areas: health, sustainability and the life science ecosystem. In 2025, the Foundation awarded DKK 11.8 billion in philanthropic grants and investments.